FIGURE 1.

A, adjusted mean (SE) change from baseline to week 52 in HbA1c, B, adjusted mean (SE) % change from baseline to week 52 in total daily insulin dose, C, adjusted mean (SE) % change from baseline to week 52 in body weight and D, adjusted mean (SE) change from baseline to week 52 in SBP (for patients with hypertension at baseline) (full analysis set). For HbA1c, body weight and SBP, adjusted mean change or % change is shown up to week 52. For insulin dose, up to week 24 insulin was recorded daily at set times, but from week 24 to 52 patients recorded the midpoint for basal and bolus insulin dose for each week. Therefore, B represents the mean % change over time (descriptive only); for HbA1c, body weight and SBP, values at week 56 (post‐treatment follow‐up visit) are mean change; for HbA1c and SBP, mixed model: change from baseline = baseline treatment study week stratum week*treatment week*baseline; for insulin dose and body weight, mixed model: log(post) – log (baseline) = log(baseline) treatment study week stratum week*treatment week*log(baseline); stratum includes one term for each combination of all stratification factors. DAPA, dapagliflozin; SBP, systolic blood pressure